Zilebesiran (RNAi) — ALN-AGT01-007
Hypertension with Elevated Cardiovascular Risk
Sponsor: Alnylam Pharmaceuticals (with Duke CRI) · Alnylam ALN-AGT01-007
About this study
Phase 3 evaluation of zilebesiran, an investigational RNAi therapeutic targeting AGT, in adults with hypertension and elevated cardiovascular risk. Coordinated with Duke Clinical Research Institute.
To evaluate whether zilebesiran, an investigational RNA-interference therapy, lowers blood pressure and cardiovascular risk in adults whose hypertension is not controlled by multiple medications.
Study details
- Sponsor
- Alnylam Pharmaceuticals (with Duke CRI)
- Protocol
- Alnylam ALN-AGT01-007
- Phase
- Phase 3
- Indication
- Hypertension with Elevated Cardiovascular Risk
- Status
- Currently Recruiting
- Principal Investigator
- Dr. William W. O'Neill, MD, FACC
High-level eligibility
- Adults 18+ with uncontrolled or treatment-resistant hypertension
- Currently on multiple antihypertensive medications
- Elevated cardiovascular risk profile
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.